Cellectar Biosciences, Inc. Resources

Patients News & Media Investors Contact

Cellectar Biosciences, Inc.

  • Home
  • About
    • Overview
    • Partnerships
    • Management Team
    • Board of Directors
  • Platform
    • Overview
    • Posters & Publications
  • Product Pipeline
    • Overview
    • Iopofosine
  • Clinical Studies
    • Overview
    • Waldenstrom’s Macroglobulinemia Phase 2 Study Active, not recruiting
    • Relapsed or Refractory Select B-Cell Malignancies Clinical Study Active, not recruiting
    • Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG Active, not recruiting
  • Patients
  • News & Media
  • Investors
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Cellectar Reports Second Quarter 2020 Financial Results and Provides a Corporate Update

Aug 10, 2020

Cellectar Announces Poster Presentation at the International Symposium on Pediatric Neuro-Oncology (ISPNO) Annual Meeting

Aug 4, 2020

Cellectar Announces Poster Presentation of Clinical Data at the American Association of Cancer Research (AACR) Annual Meeting

Jul 21, 2020

Cellectar Appoints Dr. John Friend as Chief Medical Officer

Jul 1, 2020

Cellectar to be Granted EU Patent for Phospholipid Ether (PLE) Analogs as Cancer-Targeting Drug Vehicles

Jun 11, 2020

Cellectar Biosciences Announces Closing of $20 Million Underwritten Public Offering

Jun 5, 2020

Cellectar Biosciences Announces Pricing of $20 Million Underwritten Public Offering

Jun 3, 2020

Cellectar Granted SME Status by the European Medicines Agency

Jun 1, 2020

Cellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia

May 26, 2020

Cellectar Granted Composition of Matter and Use Patent in Europe for CLR 131

May 14, 2020
RSS
    • 1...
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • ...36
    © 2025 Cellectar Biosciences, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Q&A